A Low Albumin-to-Globulin Ratio Predicts a Poor Prognosis in Patients With Metastatic Non-small-cell Lung Cancer

Lü, Ping; Ma, Yihui; Wei, Shaozhong; Liang, Xiaofeng

doi:10.3389/fmed.2021.621592

Cited by 9 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As one of the main cortisol‐binding proteins, globulin would increase with the accumulation of acute phase proteins and participated in immune and inflammatory responses. It was reported that AGR can serve as an independent prognostic indicator for non‐small cell lung cancer (NSCLC), lymphoma, and gastric cancer 33–35 . Zhou 36 showed that AGR was an independent negative factor for predicting OS of SCLC patients (our study showed a similar result).…”

Section: Discussionsupporting

confidence: 78%

“…It was reported that AGR can serve as an independent prognostic indicator for non-small cell lung cancer (NSCLC), lymphoma, and gastric cancer. [33][34][35] showed that AGR was an independent negative factor for predicting OS of SCLC patients (our study showed a similar result). Meanwhile, we also found AGR was significant in the univariate analysis of PFS.…”

Section: F I G U R E 1 Os Curves Of Sclc In the Training (A) And Vali...supporting

confidence: 81%

See 1 more Smart Citation

Construction of the prognostic model for small‐cell lung cancer based on inflammatory markers: A real‐world study of 612 cases with eastern cooperative oncology group performance score 0–1

et al. 2023

View full text Add to dashboard Cite

Objectives This research aimed to explore the relationship between pre‐treatment inflammatory markers and other clinical characteristics and the survival of small‐cell lung cancer (SCLC) patients who received first‐line platinum‐based treatment and to construct nomograms for predicting overall survival (OS) and progression‐free survival (PFS). Methods A total of 612 patients diagnosed with SCLC between March 2008 and August 2021 were randomly divided into two cohorts: a training cohort ( n = 459) and a validation cohort ( n = 153). Inflammatory markers, clinicopathological factors, and follow‐up information of patients were collected for each case. Cox regression was used to conduct univariate and multivariate analyses and the independent prognostic factors were adopted to develop the nomograms. Harrell's concordance index (C‐index) and time‐dependent receiver operating characteristic curve were used to verify model differentiation, calibration curve was used to verify consistency, and decision curve analysis was used to verify the clinical application value. Results Our results showed that baseline C‐reactive protein/albumin ratio, neutrophil/lymphocyte ratio, NSE level, hyponatremia, the efficacy of first‐line chemotherapy, and stage were independent prognostic factors for both OS and PFS in SCLC. In the training cohort, the C‐index of PFS and OS was 0.698 and 0.666, respectively. In the validation cohort, the C‐index of PFS and OS was 0.727 and 0.747, respectively. The nomograms showed good predictability and high clinical value. Also, our new clinical models were superior to the US Veterans Administration Lung Study Group (VALG) staging for predicting the prognosis of SCLC. Conclusions The two prognostic nomograms of SCLC including inflammatory markers, VALG stage, and other clinicopathological factors had good predictive value and could individually assess the survival of patients.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: F I G U R E 1 Os Curves Of Sclc In the Training (A) And Vali...supporting

confidence: 81%

Construction of the prognostic model for small‐cell lung cancer based on inflammatory markers: A real‐world study of 612 cases with eastern cooperative oncology group performance score 0–1

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Clinical data and laboratory data were collected using routine blood tests for fibrinogen (Fib), white blood cells (WBC), neutrophils (N), lymphocytes (L), monocytes (M), D dimer (D-D), platelets (PLT), hemoglobin (Hb), albumin (ALB), globulin (GLB), prealbumin (PAB) within 1 week before diagnosis. The ratio of albumin to globulin (AGR) ( 18 ), NLR, derived neutrophil to lymphocyte ratio (dNLR) ( 19 ), PLR, LMR, MLR, OPNI, SII, and SIRI were calculated.…”

Section: Methodsmentioning

confidence: 99%

Values of a novel comprehensive prognostic nutritional index (FIDA) in the prognosis of non-small cell lung cancer

Qiao,

Feng,

Han

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThis study focuses on determining the prognostic and predictive value of the comprehensive prognostic nutrition index (FIDA) in individuals undergoing treatment for Non-Small-Cell Lung Carcinoma (NSCLC).MethodsThis retrospective analysis encompassed 474 of NSCLC patients treated from January 2010 through December 2019. Employing the Lasso-COX regression approach, eight blood parameters were identified as significant prognostic indicators. These parameters contributed to the formulation of the comprehensive prognostic nutrition index FIDA. Utilizing X-tile software, the patient cohort was categorized into either a high or low FIDA group based on an established optimal threshold. The cohort was then randomly segmented into a training set and a validation set using SPSS software. Subsequent steps involved conducting univariate and multivariate regression analyze to develop a prognostic nomogram. The effectiveness of this nomogram was evaluated by calculating the AUC.ResultsAnalysis of survival curves for both the training and validation sets revealed a poorer prognosis in the high FIDA group compared to the low FIDA group. This trend persisted across various subgroups, including gender, age, and smoking history, with a statistical significance (p<0.05). Time-dependent ROC and diagnostic ROC analyses affirmed that FIDA serves as an effective diagnostic and prognostic marker in NSCLC. Moreover, Cox regression multivariate analysis established FIDA as an independent prognostic factor for NSCLC. The prognostic nomogram, integrating FIDA and clinical data, demonstrated substantial prognostic utility and outperformed the traditional TNM staging systemin predicting overall survival (OS).ConclusionFIDA emerges as a dependable predictor of outcomes for patients with NSCLC. It offers a practical, cost-effective tool for prognostication in regular clinical applications.

show abstract

“…These globulins are produced by either the liver or by components of the immune system and are critical in the immune response and chronic inflammation. Globulin has been investigated as part of the albumin/globulin ratio (albumin/total), which predicts long-term survival in early and late-stage NSCLC settings [48][49][50].…”

Section: Albuminmentioning

confidence: 99%

Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities

Stares,

Brown,

Abhi

et al. 2024

Cancers

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is a common malignancy and is associated with poor survival outcomes. Biomarkers of systemic inflammation derived from blood tests collected as part of routine clinical care offer prognostic information for patients with NSCLC that may assist clinical decision making. They are an attractive tool, as they are inexpensive, easily measured, and reproducible in a variety of healthcare settings. Despite the wealth of evidence available to support them, these inflammatory biomarkers are not yet routinely used in clinical practice. In this narrative review, the key inflammatory indices reported in the literature and their prognostic significance in NSCLC are described. Key challenges limiting their clinical application are highlighted, including the need to define the optimal biomarker of systemic inflammation, a lack of understanding of the systemic inflammatory landscape of NSCLC as a heterogenous disease, and the lack of clinical relevance in reported outcomes. These challenges may be overcome with standardised recording and reporting of inflammatory biomarkers, clinicopathological factors, and survival outcomes. This will require a collaborative approach, to which this field of research lends itself. This work may be aided by the rise of data-driven research, including the potential to utilise modern electronic patient records and advanced data-analysis techniques.

show abstract

A Low Albumin-to-Globulin Ratio Predicts a Poor Prognosis in Patients With Metastatic Non-small-cell Lung Cancer

Cited by 9 publications

References 20 publications

Construction of the prognostic model for small‐cell lung cancer based on inflammatory markers: A real‐world study of 612 cases with eastern cooperative oncology group performance score 0–1

Construction of the prognostic model for small‐cell lung cancer based on inflammatory markers: A real‐world study of 612 cases with eastern cooperative oncology group performance score 0–1

Values of a novel comprehensive prognostic nutritional index (FIDA) in the prognosis of non-small cell lung cancer

Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities

Contact Info

Product

Resources

About